DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta-burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

The aim of this review was to examine the efficacy of stepped care for the treatment of adults with depression or anxiety disorders. In consultation with the Department of Veteran’s Affairs (DVA) a number of focal conditions were identified and the evidence to support the use of stepped care in the treatment of these was reviewed. This was an iterative process between ACPMH and DVA to capture the conditions of most relevance to DVA. The conditions initially identified were depressive disorders and anxiety disorders (i.e. GAD and posttraumatic stress disorder (PTSD)); however, an initial search of the literature suggested that other anxiety disorders such as OCD might also be considered, as well as anxiety disorders and symptoms thereof taken together.

The aim of this rapid evidence assessment (REA) was to assess the evidence related to hallucinogenic drug interventions for PTSD, anxiety, and depression in adults.

This study investigated the health of Australian veterans of deployments on United Nations sanctioned peacekeeping missions to Rwanda, Somalia, Cambodia, Namibia, Western Sahara and East Timor over the period 1989-2002.

The study examined the long-term effect of peacekeeping on the mental and physical health status, health service use and quality of life of veterans who had transitioned out of full-time service.

The study found that 65% of peacekeepers reported they were in good, very good, or excellent health.  However, 30% of peacekeepers had at least one diagnosable mental health condition.

The research provides a better understanding of the long-term pathways to care and usage of health care services for peacekeepers.